Abstract:Endothelial barrier integrity is required for maintaining vascular homeostasis and fluid balance between the circulation and surrounding tissues and for preventing the development of vascular disease. Despite comprehensive understanding of the molecular mechanisms and signaling pathways mediating endothelial injury, the regulatory mechanisms responsible for endothelial regeneration and vascular repair are incompletely understood and constitutes an emerging area of research. Endogenous and exogenous reparative … Show more
“…Although it may appear surprising that the maximal FMD change was observed after the end of the treatment period, repair of dysfunctional endothelium is considered to be a gradual process taking weeks and includes restoring endothelial junctions, barrier integrity and overall endothelial regeneration. 70 As the effect appeared to be both time-and dose-dependent, it is difficult to conclude whether the maximal possible effect of SAR247799 on FMD was reached. However, as SAR247799 was at least as effective as sildenafil under the conditions evaluated, a level of clinical relevance of the S1P 1 mechanism has been established that warrants further evaluation in patients, including settings with longer treatment duration and/or with more relevant clinical endpoints.…”
agonist designed to activate endothelial S1P 1 and provide endothelial-protective properties, while limiting S1P 1 desensitization and consequent lymphocyte-count reduction associated with higher doses. The aim was to show whether S1P 1 activation can promote endothelial effects in patients and, if so, select SAR247799 doses for further clinical investigation. Methods: Type-2 diabetes patients, enriched for endothelial dysfunction (flowmediated dilation, FMD <7%; n = 54), were randomized, in 2 sequential cohorts, to 28-day once-daily treatment with SAR247799 (1 or 5 mg in ascending cohorts), placebo or 50 mg sildenafil (positive control) in a 5:2:2 ratio per cohort. Endothelial function was assessed by brachial artery FMD. Renal function, biomarkers and lymphocytes were measured following 5-week SAR247799 treatment (3 doses) to Zucker diabetic fatty rats and the data used to select the doses for human testing. Results: The maximum FMD change from baseline vs placebo for all treatments was reached on day 35; mean differences vs placebo were 0.60% (95% confidence interval [CI] −0.34 to 1.53%; P = .203) for 1 mg SAR247799, 1.07% (95% CI 0.13 to 2.01%; P = .026) for 5 mg SAR247799 and 0.88% (95% CI −0.15 to 1.91%; P = .093) for 50 mg sildenafil. Both doses of SAR247799 were well tolerated, did not affect blood pressure, and were associated with minimal-to-no lymphocyte reduction and small-to-moderate heart rate decrease. The authors confirm that the Principal Investigators for the clinical study were Grit Anderson and Leona Plum-Mörschel and that they had direct clinical responsibility for patients at the Neuss and Mainz sites, respectively. In addition, Grit Andersen was coordinating principal investigator.
“…Although it may appear surprising that the maximal FMD change was observed after the end of the treatment period, repair of dysfunctional endothelium is considered to be a gradual process taking weeks and includes restoring endothelial junctions, barrier integrity and overall endothelial regeneration. 70 As the effect appeared to be both time-and dose-dependent, it is difficult to conclude whether the maximal possible effect of SAR247799 on FMD was reached. However, as SAR247799 was at least as effective as sildenafil under the conditions evaluated, a level of clinical relevance of the S1P 1 mechanism has been established that warrants further evaluation in patients, including settings with longer treatment duration and/or with more relevant clinical endpoints.…”
agonist designed to activate endothelial S1P 1 and provide endothelial-protective properties, while limiting S1P 1 desensitization and consequent lymphocyte-count reduction associated with higher doses. The aim was to show whether S1P 1 activation can promote endothelial effects in patients and, if so, select SAR247799 doses for further clinical investigation. Methods: Type-2 diabetes patients, enriched for endothelial dysfunction (flowmediated dilation, FMD <7%; n = 54), were randomized, in 2 sequential cohorts, to 28-day once-daily treatment with SAR247799 (1 or 5 mg in ascending cohorts), placebo or 50 mg sildenafil (positive control) in a 5:2:2 ratio per cohort. Endothelial function was assessed by brachial artery FMD. Renal function, biomarkers and lymphocytes were measured following 5-week SAR247799 treatment (3 doses) to Zucker diabetic fatty rats and the data used to select the doses for human testing. Results: The maximum FMD change from baseline vs placebo for all treatments was reached on day 35; mean differences vs placebo were 0.60% (95% confidence interval [CI] −0.34 to 1.53%; P = .203) for 1 mg SAR247799, 1.07% (95% CI 0.13 to 2.01%; P = .026) for 5 mg SAR247799 and 0.88% (95% CI −0.15 to 1.91%; P = .093) for 50 mg sildenafil. Both doses of SAR247799 were well tolerated, did not affect blood pressure, and were associated with minimal-to-no lymphocyte reduction and small-to-moderate heart rate decrease. The authors confirm that the Principal Investigators for the clinical study were Grit Anderson and Leona Plum-Mörschel and that they had direct clinical responsibility for patients at the Neuss and Mainz sites, respectively. In addition, Grit Andersen was coordinating principal investigator.
“…ECs are normally quiescent with a very low turnover rate. In response to injury, expression of some transcriptional factors is induced to activate EC proliferation (42). We have shown previously that FoxM1 is markedly induced in lung ECs in the recovery phase but not in the injury phase in young adult mice following LPS challenge (27).…”
Aging is a major risk factor of high incidence and increased mortality of acute respiratory distress syndrome (ARDS) and COVID-19. We repot that aging impairs the intrinsic FoxM1-dependent endothelial regeneration and vascular repair program and causes persistent lung injury and high mortality following sepsis. Therapeutic gene transduction of FOXM1 in vascular endothelium or treatment with FDA-approved drug Decitabine was sufficient to reactivate FoxM1-dependent lung endothelial regeneration in aged mice, reverse aging-impaired resolution of inflammatory injury, and promote survival. In COVID-19 lung autopsy samples, FOXM1 expression was not induced in vascular endothelial cells of elderly patients in contrast to mid-age patients. Thus, Decitabine reactivation of FoxM1-dependent vascular repair represents a potential effective therapy for elderly COVID-19 and non-COVID-19 ARDS patients.
“…Re-endothelialization is a complex mechanobiological process, which is modulated by the proliferation and migration of resident endothelial cells from uninjured intima ( Evans et al, 2020 ; Li et al, 2021 ) and by the adhesion of circulating endothelial cells ( Tesfamariam, 2016 ; Hu et al, 2019 ). Increased circulating endothelial cells in the peripheral blood have been reported in various pathologic conditions involving severe endothelial perturbation, including inflammatory disease, acute myocardial infarction, unstable angina, and critical limb ischemia ( Makin et al, 2004 ; Lee et al, 2005 ).…”
Section: Discussionmentioning
confidence: 99%
“…Since endothelial progenitor cells (EPCs) were found in peripheral blood, circulating EPCs were regarded as the primary cell source for reconstructing the damaged endothelium ( Zhang et al, 2014 ). On the other hand, mounting evidence indicated that circulating EPCs (most likely monocytic) could not directly contribute to endothelial regeneration by forming part of the regenerating endothelium ( Evans et al, 2020 ). As a marker of endothelial injury, circulating endothelial cells detached from impaired vessels, sloughed into the circulation, and contributed to vascular repair ( Quilici et al, 2004 ; Blann et al, 2005 ).…”
Coronary stent placement inevitably causes mechanical damage to the endothelium, leading to endothelial denudation and in-stent restenosis (ISR). Re-endothelialization depends mainly on the migration of vascular endothelial cells (VECs) adjacent to the damaged intima, as well as the mobilization and adhesion of circulating VECs. To evaluate the combined contribution of VEC migration and adhesion to re-endothelialization under flow and the influence of stent, in vitro models were constructed to simulate various endothelial denudation scales (2 mm/5 mm/10 mm) and stent deployment depths (flat/groove/bulge). Our results showed that (1) in 2 mm flat/groove/bulge models, both VEC migration and adhesion combined completed the percentage of endothelial recovery about 27, 16, and 12%, and migration accounted for about 21, 15, and 7%, respectively. It was suggested that the flat and groove models were in favor of VEC migration. (2) With the augmentation of the injury scales (5 and 10 mm), the contribution of circulating VEC adhesion on endothelial repair increased. Taken together, endothelial restoration mainly depended on the migration of adjacent VECs when the injury scale was 2 mm. The adhered cells contributed to re-endothelialization in an injury scale-dependent way. This study is helpful to provide new enlightenment for surface modification of cardiovascular implants.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.